Health
Synairgen’s SNG001 advances into phase 3 COVID-19 trial – PMLiVE
UK biotech had initially been testing drug for COPD and asthma
Southampton, UK-based biotech company Synairgen has announced that a small phase 2 trial of its investigational candidate SNG001 supports advancement into phase 3 testing.
SNG001 delivers an inhaled formulation of Interferon-beta-1a (INF-beta-1a) to the lungs directly via nebulisation – INF-beta is a naturally occurring protein that controls the body’s antiviral response.
Initially, Synairgen had been evaluating the drug as a treatment for COPD and asthma, although its focus has now shifted to investigating…
-
General22 hours agoAccused of Antisemitism: Herald Sun, Israel lobby v Dandenong Clr Rhonda Garad
-
Noosa News21 hours agoMitch Power Quick Shear event gets men talking about mental health
-
Noosa News15 hours agoNRL live updates: Newcastle Knights vs Melbourne Storm, St George Illawarra Dragons vs Sydney Roosters, North Queensland Cowboys vs Canterbury Bulldogs
-
General23 hours agoThailand punches above its weight in film creativity and cross-border appeal. Here’s why